Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT06198413
PHASE1
LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
Sponsor: Innostellar Biotherapeutics Co.,Ltd
View on ClinicalTrials.gov
Summary
The goal of this study is to evaluate the safety and efficacy of LX102 gene therapy for nAMD.
Official title: A Dose-Escalation Study of LX102 Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD)
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2023-02-27
Completion Date
2029-01
Last Updated
2025-07-01
Healthy Volunteers
No
Interventions
GENETIC
LX102 subretinal injection
LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap
Locations (3)
Anhui Provincial Hospital
Hefei, Anhui, China
Zhejiang University Eye Hospital
Hangzhou, Zhejiang, China
Shanghai General Hospital
Shanghai, China